Literature DB >> 33464376

A novel evaluation method for Ki-67 immunostaining in paraffin-embedded tissues.

Eliane Pedra Dias1,2, Nathália Silva Carlos Oliveira3,4, Amanda Oliveira Serra-Campos3, Anna Karoline Fausto da Silva3, Licínio Esmeraldo da Silva3, Karin Soares Cunha3,4.   

Abstract

The Ki-67 labeling index is traditionally used to investigate tumor aggressiveness. However, no diagnostic or prognostic value has been associated to the heterogeneous pattern of nuclear positivity. The aims of this study were to develop a classification for the patterns of Ki-67-positive nuclei; to search scientific evidence for the Ki-67 expression and location throughout the cell cycle; and to develop a protocol to apply the classification of patterns of Ki-67-positive nuclei in squamous epithelium with different proliferative activities. Based on empirical observation of paraffin sections submitted to immunohistochemistry for the determination of Ki-67 labeling index and literature review about Ki-67 expression, we created a classification of the patterns of nuclear positivity (NP1, NP2, NP3, NP4, and mitosis). A semi-automatic protocol was developed to identify and quantify the Ki-67 immunostaining patterns in target tissues. Two observers evaluated 7000 nuclei twice to test the intraobserver reliability, and six evaluated 1000 nuclei to the interobserver evaluation. The results showed that the immunohistochemical patterns of Ki-67 are similar in the tumoral and non-tumoral epithelium and were classified without difficulty. There was a high intraobserver reliability (Spearman correlation coefficient > 0.9) and moderate interobserver agreement (k = 0.523). Statistical analysis showed that non-malignant epithelial specimens presented a higher number of NP1 (geographic tongue = 83.8 ± 21.8; no lesion = 107.6 ± 52.7; and mild dysplasia = 86.6 ± 25.8) when compared to carcinoma in Situ (46.8 ± 34.8) and invasive carcinoma (72.6 ± 37.9). The statistical evaluation showed significant difference (p < 0.05). Thus, we propose a new way to evaluate Ki-67, where the pattern of its expression may be associated with the dynamics of the cell cycle. Future proof of this association will validate the use of the classification for its possible impact on cancer prognosis and guidance on personalized therapy.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Biomarker; Cell cycle; Immunohistochemistry; Ki-67

Mesh:

Substances:

Year:  2021        PMID: 33464376     DOI: 10.1007/s00428-020-03010-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 2.  Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

Authors:  Christopher C Mills; E A Kolb; Valerie B Sampson
Journal:  Cancer Res       Date:  2018-01-08       Impact factor: 12.701

Review 3.  The concurrent chemoradiation paradigm--general principles.

Authors:  Tanguy Y Seiwert; Joseph K Salama; Everett E Vokes
Journal:  Nat Clin Pract Oncol       Date:  2007-02

Review 4.  Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers.

Authors:  Amy M Buckley; Niamh Lynam-Lennon; Hazel O'Neill; Jacintha O'Sullivan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-01-31       Impact factor: 46.802

5.  Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.

Authors:  Rajul K Jain; David S Hong; Aung Naing; Jennifer Wheler; Thorunn Helgason; Nai-Yi Shi; Yash Gad; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 7.  The cell cycle and cancer.

Authors:  Gareth H Williams; Kai Stoeber
Journal:  J Pathol       Date:  2011-10-28       Impact factor: 7.996

Review 8.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

9.  Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels.

Authors:  Michal Sobecki; Karim Mrouj; Jacques Colinge; François Gerbe; Philippe Jay; Liliana Krasinska; Vjekoslav Dulic; Daniel Fisher
Journal:  Cancer Res       Date:  2017-03-10       Impact factor: 12.701

Review 10.  The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis.

Authors:  Denghua Pan; Kanglai Wei; Yanxin Ling; Shitao Su; Meilin Zhu; Gang Chen
Journal:  Med Sci Monit       Date:  2015-03-25
View more
  3 in total

Review 1.  The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.

Authors:  Giuseppe Pelosi; William D Travis
Journal:  Pathologica       Date:  2021-10

2.  Proposal for a New Diagnostic Histopathological Approach in the Evaluation of Ki-67 in GEP-NETs.

Authors:  Pinuccia Faviana; Laura Boldrini; Carlo Gentile; Paola Anna Erba; Enrico Sammarco; Francesco Bartoli; Enrica Esposito; Luca Galli; Piero Vincenzo Lippolis; Massimo Bardi
Journal:  Diagnostics (Basel)       Date:  2022-08-13

3.  The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index.

Authors:  N Tancredi-Cueto; G Vigil-Bastitta; R Bologna-Molina; V Beovide-Cortegoso
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.